Clinical trial
Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1…
NCT00396006 · Baxalta now part of Shire, Industry · Completed
Key facts
| NCT number | NCT00396006 |
|---|---|
| Title | Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor) |
| Official title | The Effect of Augmentation Therapy With ARALAST Fraction IV-1 (ARALAST) Alpha1-Proteinase Inhibitor (α1-PI) on the Level of α1-PI and Other Analytes in the Bronchoalveolar (BAL) Epithelial Lining Fluid (ELF) |
| Lead sponsor | Baxalta now part of Shire, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Alpha 1-Antitrypsin Deficiency |
| Intervention type | Biological |
| Interventions | Alpha1-Proteinase Inhibitor |
| Enrollment | 21 |
| Start date | Oct 27, 2006 |
| Primary completion | Dec 14, 2007 |
| Completion | Dec 14, 2007 |
| First posted | Nov 6, 2006 |
| Last update posted | May 13, 2021 |
| Countries | Australia, New Zealand |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: